(E)-methyl 3-(4-(o-tolylethynyl)phenyl)acrylate | 1420837-05-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-methyl 3-(4-(o-tolylethynyl)phenyl)acrylate
• CAS: 1420837-05-3
• 化学式: C₁₉H₁₆O₂
• 分子量: 276.335
• InChiKey: JPHDRZVOCMBLCN-WYMLVPIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.58
• 重原子数：
  21.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  26.3
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  (E)-methyl 3-(4-(o-tolylethynyl)phenyl)acrylate 在 lithium hydroxide monohydrate 、 水 作用下， 以 四氢呋喃 为溶剂， 以85%的产率得到(E)-3-[4-[2-(2-methylphenyl)ethynyl]phenyl]prop-2-enoic acid
  参考文献：
  名称：

  Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability

  摘要：

  The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging as a new target for the treatment of type 2 diabetes. Several FFA1 agonists are known, but the majority of these suffer from high lipophilicity. We have previously reported the FFA1 agonist 3 (TUG-424). We here describe the continued structure-activity exploration and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on glucose tolerance in mice.

  DOI：

  10.1021/jm301470a
• 作为产物：
  描述：

  methyl (2E)-3-4-[2-(trimethylsilyl)ethynyl]phenylprop-2-enoate 在 copper(l) iodide 、 sodium tetrachloropalladate(II) 、 四甲基乙二胺 、 potassium carbonate 、 2-二叔丁基膦-1-苯基吲哚 作用下， 以 甲醇 、 水 为溶剂， 反应 1.0h， 生成 (E)-methyl 3-(4-(o-tolylethynyl)phenyl)acrylate
  参考文献：
  名称：

  Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability

  摘要：

  The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging as a new target for the treatment of type 2 diabetes. Several FFA1 agonists are known, but the majority of these suffer from high lipophilicity. We have previously reported the FFA1 agonist 3 (TUG-424). We here describe the continued structure-activity exploration and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on glucose tolerance in mice.

  DOI：

  10.1021/jm301470a